3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Basal Cell
4
Recurrence
3
Basal Cell Nevus Syndrome
3
Skin Neoplasms
2
Multiple Myeloma
2
Medulloblastoma
2
Thrombocytosis
1
Thrombocythemia, Essential
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pancreatic Diseases
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hepatoblastoma
1
Hemorrhagic Disorders
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Glioma
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma
1
Bone Marrow Diseases
1
Blood Platelet Disorders
1
Blood Coagulation Disorders
1
Astrocytoma
1
Interventions
Leucovorin
38
Fluorouracil
36
Oxaliplatin
34
Bevacizumab
34
Irinotecan
32
Cetuximab
23
Capecitabine
18
Panitumumab
14
IFL protocol
7
Folfox protocol
6
Celecoxib
6
Radiotherapy
5
Nivolumab
5
Magnetic Resonance Spectroscopy
5
Immunohistochemistry
5
Gene Expression Profiling
5
regorafenib
4
pembrolizumab
4
dehydroftorafur
4
Ramucirumab
4
Fluorodeoxyglucose F18
4
Floxuridine
4
aflibercept
3
Surgical Procedures, Operative
3
Sorafenib
3
Radiosurgery
3
Ipilimumab
3
Gemcitabine
3
Fentanyl
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Colonic Neoplasms
×
sonidegib
×
Clear all
NCT02002689
2016-05-02
SIGNATURE
Novartis
Phase 2
Terminated
10 enrolled
9 charts